Our results suggest that the inhibition of both ALDH1A1 and ALDH3A1, and particularly their reducing-agent-dependent NAD+ reduction activity, should be viewed as targets for the development of anti-cancer therapies. The gene discussed is ALDH1A1; the disease is cancer.